How KIO-401 Positions Kiora as a Late-Stage Retinal Therapeutics Company
Newsfile Corp•19/11/2026•07:00 ET
1
Key Highlights
- ➤Kiora plans multinational Phase 3 CRAO registration trial starting in 2027
- ➤KIO-401 previously evaluated in Phase 2 and Phase 3 CRAO studies in Japan
- ➤Kiora plans Phase 2b NAION trial for oral calpain inhibitor KIO-401
- ➤KIO-401 targets sudden vision loss from central retinal artery occlusion
Expert Statements
Brian M. Strem, President and CEO of Kiora Pharmaceuticals
“KIO-401 (mitucapistat), an investigational oral calpain inhibitor for sudden vision loss caused by central retinal artery occlusion (CRAO).”
San Diego, California--(Newsfile Corp. - November 19, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has posted an on-demand video featuring President and CEO Brian M. Strem, Ph.D., discussing the in-licensing of KIO-401 (mitucapistat), an investigational oral calpain inhibitor for sudden vision loss caused by central retinal artery occlusion (CRAO). Click here or on the following image to view the video.
https://d1io3yog0oux5.cloudfront.net/_4b761e6c9445bbf9c0fa832060f4ff8d/kiorapharma/files/Brian_Strem_Interview_Audiogram_re_KIO-401_with_FWS.mp4
Get started
Create a free account to read the full story.
